Login to Your Account



Hedge Fund Wants Sale Of Company

Nabi Shareholders Rumbling, Citing Management 'Blunders'

By Randall Osborne


Monday, August 21, 2006
The letter from a major shareholder of Nabi Pharmaceuticals Inc., attacking CEO Thomas McLain for the company's "abysmal" performance and "bargain-basement stock price," sent Nabi's shares up about 5 percent on the day it was made public last week, but the story may not be over. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription